OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
108
Results
Show all
Save search
Copy query
Show results for
Unknown
(100)
Proteomics
(4)
Transcriptomics
(3)
Genomics
(1)
Organisms
Homo sapiens
(8)
Repository
pride
(4)
biostudies-arrayexpress
(3)
EGA
(1)
Tissue
Cell culture
(1)
Hepatocyte
(1)
Liver
(1)
Lymph node
(1)
Skin
(1)
Disease
Hepatocellular carcinoma
(1)
Technology Type
Mass Spectrometry
(4)
Shotgun proteomics
(3)
Affinity purification coupled with mass spectrometry proteomics
(1)
Instrument Platform
MoFlo Legacy cell sorter (Beckman Coulter)
(1)
PC
(1)
Publication Date
2018
(1)
2015
(1)
2011
(1)
2025
(1)
2023
(1)
2022
(1)
2020
(1)
Study type
Transcription profiling by array
(3)
Release Date
2025
(13)
2021
(13)
2022
(12)
2018
(10)
2015
(9)
2020
(9)
2017
(8)
2024
(7)
2023
(6)
2019
(5)
2014
(3)
2016
(2)
2013
(2)
2011
(1)
2026
(1)
2008
(1)
2007
(1)
Lab affiliation
Aix-Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), Turing Center for Living Systems, Marseille, France
(1)
Biozentrum, University of Basel, 4056 Basel, Switzerland
(1)
Biozentrum, University of Basel, Switzerland
(1)
Vall d'Hebron Institute of Oncology
(1)
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Not available
S-EPMC5087318
|
biostudies-literature
Cite
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Not available
S-EPMC6656445
|
biostudies-literature
Cite
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Not available
S-EPMC5551492
|
biostudies-literature
Cite
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers.
Not available
S-EPMC8185105
|
biostudies-literature
Cite
Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity.
Not available
S-EPMC2275387
|
biostudies-literature
Cite
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Not available
S-EPMC6224305
|
biostudies-literature
Cite
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Not available
S-EPMC5834036
|
biostudies-literature
Cite
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
Not available
S-EPMC8595766
|
biostudies-literature
Cite
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction.
Not available
S-EPMC11749429
|
biostudies-literature
Cite
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Not available
S-EPMC4968773
|
biostudies-literature
Cite
Previous
page
1 / 11
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
11
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
